New article on FLA treatment of prostate cancer published in JVIR. CLS partner, Dr Eric Walser, UTMB, is one of the co-authors.
A new article, regarding treatment with focal laser ablation (FLA) of prostate cancer, was published in
Journal of Vascular and Interventional Radiology (JVIR) Volume 30, Issue 3, March 2019, pages 401-409.e2. The article describes treatment and follow-up of 120 patients with prostate cancer, that have been treated with focal laser ablation at the University of Texas, Medical Branch (UTMB).
- Dr Eric Walser’s clinical work, within the area od FLA treatment of prostate cancer, is an excellent support in our mission to position and market our TRANBERG®-system. The study described in this article does not include any treatments carried out with CLS products. Our products are, since a while back, standard in Eric Walser’s FLA treatment procedure, says Lars-Erik Eriksson, CEO of CLS.
Below you find a link to the article. The link will be active for a limited period of time.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: email@example.com
Clinical Laserthermia Systems AB (publ),develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Berlin, Germany and Boston, MA, USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser:Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, E-mail: firstname.lastname@example.org. Further information is available on www.clinicallaser.se